Correlation Between Arcus Biosciences and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Arcus Biosciences and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arcus Biosciences and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arcus Biosciences and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Arcus Biosciences and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arcus Biosciences with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arcus Biosciences and Acrivon Therapeutics,.

Diversification Opportunities for Arcus Biosciences and Acrivon Therapeutics,

0.48

Correlation Coefficient

Arcus Biosciences  Acrivon Therapeutics,

Very weak diversification

The 3 months correlation between Arcus and Acrivon is 0.48. Overlapping area represents the amount of risk that can be diversified away by holding Arcus Biosciences and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Arcus Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arcus Biosciences are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Arcus Biosciences i.e., Arcus Biosciences and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Arcus Biosciences and Acrivon Therapeutics,

Given the investment horizon of 90 days Arcus Biosciences is expected to under-perform the Acrivon Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Arcus Biosciences is 1.47 times less risky than Acrivon Therapeutics,. The stock trades about -0.1 of its potential returns per unit of risk. The Acrivon Therapeutics, Common is currently generating about -0.07 of returns per unit of risk over similar time horizon. If you would invest  726.00  in Acrivon Therapeutics, Common on October 13, 2024 and sell it today you would lose (179.00) from holding Acrivon Therapeutics, Common or give up 24.66% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Arcus Biosciences  vs.  Acrivon Therapeutics, Common

Arcus Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Arcus Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in February 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Arcus Biosciences and Acrivon Therapeutics,

The main advantage of trading using opposite Arcus Biosciences and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arcus Biosciences position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Arcus Biosciences and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.